Overview Financials News + Filings Key Docs Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Inv. presentation Quarterly results
|
Acrivon Therapeutics, Inc.
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
08/11/2023 |
8-K
| Quarterly results
Docs:
|
"Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights WATERTOWN, Massachusetts, August 11, 2023 - Acrivon Therapeutics, Inc. , a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today reported financial results for the second quarter ended June 30, 2023 and provided business highlights. “The Acrivon team has made significant progress during the second quarter, both on the clinical and preclinical development fronts, as well as with the expansion of our board and executive leadership team with strategic additions,” said Peter Blume-Jensen, ..." |
|
06/05/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
05/09/2023 |
8-K
| Quarterly results |
05/01/2023 |
8-K
| Investor presentation |
05/01/2023 |
8-K
| Quarterly results |
04/25/2023 |
8-K
| Quarterly results |
03/28/2023 |
8-K
| Quarterly results |
03/13/2023 |
8-K
| Investor presentation |
11/17/2022 |
8-K
| Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Even... |
|
|